Savara (SVRA) Depreciation & Amortization (IS) (2010 - 2026)
Savara (SVRA) reported Depreciation & Amortization (IS) of $24000.0 for Q1 2026, down 20.0% year-over-year from $30000.0 in Q1 2025, and up 318.18% quarter-over-quarter from -$11000.0 in Q4 2025.
Savara (SVRA) Depreciation & Amortization (IS) (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Depreciation & Amortization (IS) data on file, last reported at $24000.0 in Q1 2026.
- Depreciation & Amortization (IS) for Q1 2026 came in at $24000.0, down 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $83000.0 (down 35.16% YoY), and the FY2025 annual result was $87000.0, down 33.08% from the prior year.
- Depreciation & Amortization (IS) climbed to $24000.0 in Q1 2026 per SVRA's latest filing, from -$11000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (IS) peaked at $36000.0 in Q3 2025 and troughed at -$11000.0 in Q4 2025.
- A 5-year average of $20705.9 and a median of $30000.0 in 2023 frame the typical range for Depreciation & Amortization (IS).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (IS) jumped 357.14% in 2023, then tumbled 134.38% in 2025.
- A 5-year view of Depreciation & Amortization (IS) shows it stood at $7000.0 in 2022, then surged by 357.14% to $32000.0 in 2023, then changed by 0.0% to $32000.0 in 2024, then plunged by 134.38% to -$11000.0 in 2025, then jumped by 318.18% to $24000.0 in 2026.
- Business Quant data shows SVRA's Depreciation & Amortization (IS) at $24000.0 in Q1 2026, -$11000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 127,436.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 12.00 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 47,000.00 |